Advanced Enzyme Technologies approves ₹69.7 crore buyback
Key highlights
- Advanced Enzyme Technologies approved a ₹69.7 crore open-market buyback at a ceiling price of ₹500 per share.
- The buyback covers up to 13.94 lakh shares, equal to 1.24% of paid-up capital.
- Advanced Enzyme Technologies will acquire JC Biotech’s remaining 4.28% stake for ₹7.98 crore.
- Q1 FY27 revenue was ₹190 crore, EBITDA was ₹51.1 crore and net profit was ₹37 crore.
powered by IRIS

Advanced Enzyme Technologies Limited approved an open-market share buyback of up to ₹69.7 crore on August 8, 2026, while also approving the ₹7.98 crore acquisition of the remaining 4.28% stake in JC Biotech Private Limited. The transactions will make JC Biotech a wholly owned subsidiary upon completion and provide a capital-return mechanism for eligible shareholders.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
What did Advanced Enzyme Technologies approve on August 8, 2026?
Advanced Enzyme Technologies approved an open-market buyback of up to 13.94 lakh equity shares at a maximum price of ₹500 per share. The maximum outlay is ₹69.7 crore, and the proposed repurchase represents up to 1.24% of the company’s paid-up capital. Promoters, the promoter group and persons in control are excluded from participation in the buyback.
The board took the decision alongside approval of the company’s unaudited financial results for the quarter ended June 30, 2026. Advanced Enzyme reported revenue of ₹190 crore, EBITDA of ₹51.1 crore and net profit of ₹37 crore for Q1 FY27. Its EBITDA margin for the quarter stood at 26.9%.
The buyback is a capital-allocation decision that reduces the number of shares available for repurchase within the specified limit. The company has set ₹500 per share as the ceiling price rather than a fixed purchase price, as the transaction is proposed through the open-market route.
How will JC Biotech become a wholly owned subsidiary?
Advanced Enzyme approved the acquisition of the outstanding 4.28% stake in JC Biotech Private Limited for ₹7.98 crore, or ₹90 per share. Advanced Enzyme already held 95.72% in JC Biotech, so the approved transaction will take its holding to 100% when completed.
JC Biotech has been part of Advanced Enzyme’s subsidiary network for several years. During the financial year ended March 31, 2017, Advanced Enzyme acquired 1.43 crore equity shares of JC Biotech at ₹35 per share. It later acquired an additional 15% stake in JC Biotech on May 29, 2021.
The company stated that the full acquisition is intended to streamline operations. Since JC Biotech was already a subsidiary, the purchase removes the remaining minority shareholding and gives Advanced Enzyme complete ownership of the unit.
Got a follow-up? Ask IRIS
Why is Advanced Enzyme funding Advanced Nutrazyme?
Advanced Enzyme also approved an infusion of up to ₹2 crore into Advanced Nutrazyme Private Limited, its wholly owned subsidiary. The company said the funds may be deployed in one or more tranches, providing flexibility on the timing of the capital infusion.
The announcement places the Nutrazyme funding alongside the JC Biotech transaction as part of a broader update on the company’s subsidiary structure. While the stated information does not quantify the financial effect of the funding, it confirms that the board has authorised the additional capital support.
Advanced Enzyme had 12 subsidiaries as of March 31, 2021. Its earlier expansion steps included the incorporation of Advanced Enzymes Europe BV as a wholly owned subsidiary on July 11, 2017, the acquisition of certain assets and liabilities of Biomedic Labs in October 2017, and the acquisition of a 51% controlling stake in SciTech Specialities Private Limited in January 2021.
What do the results and subsidiary data show?
Advanced Enzyme’s Q1 FY27 results reported ₹190 crore in revenue and ₹37 crore in net profit, with EBITDA of ₹51.1 crore. The reported 26.9% EBITDA margin provides the operating-margin measure disclosed with the quarterly update.
Subsidiary-level details cited for JC Biotech show revenue of ₹19.5 crore and profit after tax of ₹1 crore. Evoxx reported revenue of ₹7.4 crore but recorded a loss after tax of ₹1.8 crore. These figures show that subsidiary performance varied across the group.
Advanced Enzyme operates in the healthcare sector under pharmaceuticals and drugs and is described as India’s largest enzyme manufacturer in the pharmaceuticals and biotechnology segment. The company’s stated market capitalisation was ₹3,321 crore. Promoter holding increased to 43.56% in the September 2026 quarter from 43.24% in the prior disclosed quarter.
How do these decisions affect shareholders and operations?
The buyback gives eligible public shareholders a mechanism through which shares may be repurchased in the market, subject to the maximum outlay, price ceiling and quantity approved by the board. Because promoters and persons in control are excluded, the buyback is restricted to other eligible shareholders.
The JC Biotech purchase is separate from the buyback and changes the ownership structure of an existing subsidiary. Full ownership will eliminate the residual 4.28% minority interest in JC Biotech, while the Nutrazyme infusion provides approved funding capacity for another wholly owned unit. The available disclosures frame both subsidiary actions as corporate-structuring and funding measures rather than as separately quantified earnings events.
Conclusion
Advanced Enzyme’s August 8 decisions combine a ₹69.7 crore open-market buyback with the purchase of JC Biotech’s outstanding minority stake and up to ₹2 crore of funding for Advanced Nutrazyme. The company reported ₹190 crore of revenue, ₹51.1 crore of EBITDA and ₹37 crore of net profit for Q1 FY27 alongside these board approvals.
Investors can monitor the execution of the open-market buyback within its ₹500-per-share ceiling and the completion of the JC Biotech acquisition. The disclosed next steps also include the planned deployment of the Advanced Nutrazyme infusion in one or more tranches.


